Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert
Patent
1993-05-17
1994-08-23
Page, Thurman K.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Implant or insert
424485, 424486, 424433, A61K 950, A61K 914
Patent
active
053405862
ABSTRACT:
Compositions and methods which are effective to prevent symptoms of loss of ovarian function (e.g., in oophorectomized women) over a period of time are described, consisting essentially of an effective amount of an estrogenic composition and an effective amount of an androgenic composition. The levels of estrogens and androgens employed are sufficient to reduce bone mineral density loss and minimize other side effects observed after oophorectomy, and at such low doses as to minimize any adverse impact on the patient's long-term prognosis or (in the case of testosterone) result in additional side effects.
REFERENCES:
patent: 3731683 (1973-05-01), Zaffaroni
patent: 3797494 (1974-03-01), Zaffaroni
patent: 4264575 (1981-04-01), Zimmerman et al.
patent: 4336243 (1982-06-01), Sanvordeker et al.
patent: 4762717 (1988-08-01), Crowley, Jr.
patent: 5211952 (1993-05-01), Spicer et al.
Watts et al, "Effects of Oral Estrogens and Esterified Estrogens +Androgen on Bone Mineral Density in Post-Menopausal Women", The 2nd Annual Meeting North American Menopause Society Programe, S-F16, Sep. 25-28, 1991.
Bergkvist et al., "The Risk of Breast Cancer After Estrogen and Estrogen-Progestin Replacement", N.E.J. of Med., 321: 5, pp. 293-297 (Aug. 3, 1989).
Burger et al., "The Management of Persistent Menopausal Symptoms with Oestradiol-Testosterone Implants: Clinical, Lipid and Hormonal Results", Maturitas, 6: 351-358 (1984).
Chetkowski et al., "Biologic Effects of Transdermal Estradiol", N.E.J. of Med., 314: 5, pp. 1615-1620 (Jun. 19, 1986).
Conn et al., "Gonadotropin-Releasing Hormone and its Analogues", N.E.J. of Med., 324: 2, pp. 93-103 (Jan. 10, 1991).
Cowsar et al., "Biodegradable and Nonbiodegradable Fibrous Delivery Systems", Long Acting Contraceptive Delivery Systems pp. 145-162 (eds. Zatuchni et al. 1984).
Diczfalusy et al., "Some Pharmacokinetic and Pharmacodynamic Properties of Vaginal Delivery Systems That Release Small Amounts of Progestogens at a Near Zero-Order Rate", Long-Acting Contraceptive Delivery Systems, pp. 213-227 (eds. Zatuchni et al. 1984).
Donnez et al., "Treatment of Uterine Fibroids with Implants of Gonadotropin-releasing Hormone Agonist: Assessment by Hysterography", Fertility and Sterility, 51: 6, pp. 947-950 (Jun. 1989).
Farish et al., "The Effects of Hormone Implants on Serum Lipoproteins and Steroid Hormones in Bilaterally Oophorectomised Women", Act Endocrinologica, 106:116-120 (1984).
Ferguson et al., "Compudose: An Implant System for Growth Promoting and Feed Efficiency in Cattle", J. of Controlled Release, 8:45-54 (1988).
George et al., Int. J. Fertil., 34: 19-24 (1989).
Garza-Flores et al., "Development of a Low-Dose Monthly Injectable Contraceptive" Contraception 30: 79 (1984).
Gennant et al., "Quantitative Computed Tomography of Vertebral Spongiosa: A Sensitive Method for Detecting Early Bone Loss After Oophorectomy", Annals of Internal Medicine, 97: 5, pp. 699-705 (Nov. 1982).
Mertola et al., "Successful Treatment of Severe Premenstrual Syndrome by Combined Use of Gonadotropin-Releasing Hormone Agonist and Estrogen/Progestin", J. of Clin. Endocrinology and Metabolism, pp. 252A-252F (1991).
Lobo et al., "Subdermal Estradiol Pellets Following Hysterectomy and Oophorectomy", Amer. Journal of Obstetrics & Gyn. 138: 714-719 (1980).
Nezhat et al., "Estradiol Implants for Conception Control", Amer. Journal of Obstetrics & Gyn. 138: 1151-1156 (1980).
Notelovitz et al., "Influence of Extended Treatment With Oral Estrogens/Androgen Combination on Lipids and Lipoproteins in Surgically Menopausal Women", North American Menopause Society, 1991 Meeting Abstract, S-B5 (Montreal Canada 1991).
Nuwayser et al., "Microencapsulation of Contraceptive Steroids", Long-Acting Contraceptive Delivery Systems, pp. 65-75 (eds. Zatuchni et al. 1984).
Pike et al., "LHRH Agonists and the Prevention of Breast and Ovarian Cancer", Br. J. Cancer, 60: 142-148 (1989).
Pitt et al., "Capronor--A Biodegradable Delivery System for Levonorgestrel", Long-Acting Contraceptive Delivery Systems, pp. 48-63 (eds. Zatuchni et al. 1984).
Ralston et al., "Effect of Subdermal Oestrogen and Oestrogen/Testosterone Implants on Calcium and Phosphorus Homeostasis After Oophorectomy", Maturitas., 6: 341-344 (1984).
Roy et al., "Vaginal Ring Clinical Studies: Update", Long-Acting Contraceptive Delivery Systems, pp. 581-594 (eds. Zatuchni et al. 1984).
Sandow et al., "Clinical Pharmacokinetics of LHRH Analogues", LHRH Analogues in Gynaecology, pp. 17-31.
Sherwin et al., "Postmenopausal Estrogen and Androgen Replacement and Lipoprotein Lipid Concentrations", Am. J. Obstet. Gynecol., 156: 414-419 (1987).
Stanczyk et al., "A Randomized Comparison of Nonoral Estradiol Delivery in Postmenopausal Women", Am. J. Obstet. Gynecol. 159: 6, pp. 1540-1546 (Dec. 1988).
Urman et al., "Elevated Serum Testosterone, Hirsutism, and Virilism Associated With Combined Androgen-Estrogen Hormone Replacement Therapy", Obstetrics & Gynecology 77: 4, pp. 595-598 (Apr. 1991).
Youngs et al., "Effects of an Oral Estrogen-Androgen Preparation on Lipoprotein Lipids in Postmenopausal Women: a Pilot Study", North American Menopause Society 1991 Meeting Abstract, P-130 (Montreal Canada 1991).
Zorn et al., "Treatment of Endometriosis with a Delayed Release Preparation of the Agonist D-Trp.sup.8 -luteinizing Hormone-releasing Hormone: Long-term Follow-up in a Series of 50 Patients", Fertility & Sterility, 53: 3, pp. 401-406 (Mar. 1990).
Gilley et al., "Development of Controlled-Release Progesterone Microcapsules for the Regulation of Fertility During Lactation", Southern Research Inst. 73-74.
Kaufman, M. et al., J. Clin. Oncol., y: 1113-19 (1989).
Hahn, et al., "Development of Microencapsulated Norgestimate as a Long-Acting Contraceptive", Long-Acting Contraceptive Delivery Systems, pp. 97-112 (eds. Zatuchni et al., 1984).
Hsieh et al., "Subecutaneous Controlled Administration of Estradiol From Compudose Implants: In Vitro and In Vivo Evaluations", Rutgers University, pp. 134-135.
Hsieh et al., "Enhanced Release of Drugs From Silicone Elastomers (I) Release Kinetics of Pineal and Steroidal Hormones", RVG Development and Industrial Pharmacy, 11(6&7) 1391-1410 (1985).
Jackanicz, Theordore M., "Vaginal Ring Steroid-Releasing Systems", Long-Acting Contraceptive Delivery Systems, pp. 200-211 (eds. Zatuchni et al., 1984).
Lewis et al., "Polymeric Considerations in the Design of Microencapsulation of Contraceptive Steroids", Long-Acting Contraceptive Delivery Systems, pp. 76-95 (eds. Zatuchni et al., 1984).
Lewis, Danny H., "Controlled Release of Bioactive Agents from Lactide/Glycolide Polymers", Stolle Research and Development Corporation, pp. 1-43.
Pike Malcolm C.
Spicer Darcy V.
Azpuru Carlos
Page Thurman K.
University of Southern California
LandOfFree
Methods and formulations for use in treating oophorectomized wom does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and formulations for use in treating oophorectomized wom, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and formulations for use in treating oophorectomized wom will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-501302